HC Wainwright Has Bullish Estimate for AVTX FY2026 Earnings

Avalo Therapeutics, Inc. (NASDAQ:AVTX – Free Report) – Equities researchers at HC Wainwright boosted their FY2026 earnings per share (EPS) estimates for shares of Avalo Therapeutics in a report released on Friday, November 6th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings of ($2.43) per share for the year, up from their previous forecast of ($2.76). HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Avalo Therapeutics’ current full-year earnings is ($2.52) per share. HC Wainwright also issued estimates for Avalo Therapeutics’ Q4 2026 earnings at ($0.55) EPS, Q1 2027 earnings at ($0.54) EPS, Q2 2027 earnings at ($0.55) EPS, Q3 2027 earnings at ($0.56) EPS, Q4 2027 earnings at ($0.57) EPS and FY2027 earnings at ($2.23) EPS.

Avalo Therapeutics (NASDAQ:AVTX – Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.25.

AVTX has been the subject of a number of other research reports. Wedbush dropped their price objective on Avalo Therapeutics from $22.00 to $20.00 and set an “outperform” rating for the company in a research report on Friday, November 6th. Cantor Fitzgerald restated an “overweight” rating on shares of Avalo Therapeutics in a report on Wednesday, September 16th. Wall Street Zen upgraded shares of Avalo Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 7th. Guggenheim cut shares of Avalo Therapeutics from a “buy” rating to a “neutral” rating in a research note on Friday, October 23rd. Finally, BTIG Research lowered their price target on shares of Avalo Therapeutics to $10.00 and set a “buy” rating for the company in a report on Friday, October 23rd. Eleven equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $36.82.

View Our Latest Stock Report on Avalo Therapeutics

Avalo Therapeutics Stock Performance

Shares of NASDAQ:AVTX opened at $8.51 on Tuesday. Avalo Therapeutics has a 52-week low of $6.53 and a 52-week high of $24.27. The stock’s fifty day simple moving average is $12.78 and its 200-day simple moving average is $15.72.

Insider Buying and Selling

In other news, CFO Christopher Sullivan sold 12,394 shares of the company’s stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $16.33, for a total value of $202,394.02. Following the completion of the transaction, the chief financial officer directly owned 39,900 shares in the company, valued at approximately $651,567. This represents a 23.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 23,258 shares of company stock worth $395,434. Insiders own 4.46% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. Aberdeen Group plc lifted its stake in Avalo Therapeutics by 83.3% in the third quarter. Aberdeen Group plc now owns 223,908 shares of the company’s stock valued at $3,433,000 after buying an additional 101,739 shares during the last quarter. Fisher Asset Management LLC bought a new stake in Avalo Therapeutics in the 3rd quarter valued at about $4,852,000. Nan Fung Trinity HK Ltd. boosted its stake in Avalo Therapeutics by 161.4% during the 3rd quarter. Nan Fung Trinity HK Ltd. now owns 189,000 shares of the company’s stock valued at $2,897,000 after purchasing an additional 116,700 shares during the period. CenterBook Partners LP boosted its stake in Avalo Therapeutics by 15.4% during the 3rd quarter. CenterBook Partners LP now owns 153,344 shares of the company’s stock valued at $2,351,000 after purchasing an additional 20,475 shares during the period. Finally, Squarepoint Ops LLC boosted its stake in Avalo Therapeutics by 624.9% during the 2nd quarter. Squarepoint Ops LLC now owns 589,245 shares of the company’s stock valued at $10,889,000 after purchasing an additional 507,960 shares during the period. Institutional investors own 87.06% of the company’s stock.

Key Stories Impacting Avalo Therapeutics

These are some of the AVTX stories that stood out recently:

About Avalo Therapeutics

(Get Free Report)

Avalo Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for immune-mediated and inflammatory diseases. The company does not have marketed products and is centered on advancing drug candidates through clinical development. Its lead candidate, AVTX-009, is a monoclonal antibody that targets interleukin-1 beta (IL-1β), an inflammatory signaling protein. Avalo is developing the therapy for hidradenitis suppurativa, a chronic inflammatory skin disease, and has described potential applications in other inflammatory conditions.

Featured Stories

Earnings History and Estimates for Avalo Therapeutics (NASDAQ:AVTX)

Receive News & Ratings for Avalo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.